RecruitingPhase 2NCT05892614

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Studying Interstitial lung disease

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
aTyr Pharma, Inc.
Principal Investigator
Lisa Carey
aTyr Pharma, Inc.
Intervention
efzofitimod 450 mg(drug)
Enrollment
25 enrolled
Eligibility
18 years · All sexes
Timeline
20232026

Study locations (13)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05892614 on ClinicalTrials.gov

Other trials for Interstitial lung disease

Additional recruiting or active studies for the same condition.

See all trials for Interstitial lung disease

← Back to all trials